Akums Drugs & Pharmaceuticals, India’s largest contract development and manufacturing organisation (CDMO), has unveiled a cutting-edge sterile manufacturing facility dedicated to producing lyophilised products. This marks a strategic leap in the company’s growth journey, enhancing its capabilities in sterile dosage manufacturing.
The facility, now operational, is equipped to manufacture lyophilised injectables, vials, ampoules, Form-Fill-Seal (FFS) products, and eye and ear drops. This expansion aligns with Akums’ goal to meet the surging global demand for advanced pharmaceutical solutions across various therapeutic areas.
The global market for lyophilised injectables was valued at USD 3,365.4 million in 2023 and is projected to reach USD 4,978.3 million by 2030, with a compound annual growth rate (CAGR) of 5.6 per cent. Lyophilisation, a process that enhances stability and extends the shelf life of sensitive compounds, is critical for addressing specialised therapeutic needs.
Akums’ facility leverages technology to produce high-quality lyophilised products, offering robust production capacity and flexibility to handle multiple vial sizes. This enables the company to serve a wide range of healthcare requirements efficiently.
Speaking about the development, Sanjeev Jain, Managing Director of Akums Drugs & Pharmaceuticals, said, “We are excited to announce our entry into lyophilised injectables, marking a significant milestone in our journey to provide world-class pharmaceutical solutions. Our new facility is primed to meet the growing global demand for lyophilised drugs with the highest standards of quality and safety.”
The facility adheres to stringent global quality standards and ensures compliance with international regulatory requirements, further reinforcing Akums’ position as a trusted partner for pharmaceutical companies.
Sandeep Jain, Managing Director, added, “The addition of lyophilisation capabilities will enable us to better serve the pharmaceutical industry by offering advanced sterile manufacturing solutions across a range of therapeutic categories. This expansion equips us to cater to diverse healthcare needs with enhanced efficiency.”
_20250104153612_original_image_21.webp)
